Skip to main content

Table 1 Demographic parameters and clinical characteristics in the studied cases

From: COVID-19’s effects on the Egyptian population’s brain: Could MRI and specialized MR spectroscopic analysis be beneficial?

Demographic and clinical parameters

All patients

(n = 118)

Non-haemorrhagic forms

(n = 63)

Haemorrhagic forms

(n = 55)

P value

Sex*

    

 Male

91 (77.2%)

51 (80.9%)

40 (72.7%)

0.38

 Female

27 (22.8%)

12 (19%)

15 (27.2%)

 

Age (years)*

Mean age of 52 ± 10 (12–78)

Mean age = 58 (12–71)

Mean age of 65 (49–78)

0.13

Time interval from onset of respiratory symptoms to first hospital admission, mean-range*

14 d (0–28)

12 d (8–28)

8 d (0–12)

0.81

Time interval from onset of neurological symptoms to brain MRI (d) mean-range*

30 h (4 h–3d)

48 h (36 h–3d)

8 h (4–12 h)

0.01

Admission to ICU*

101 (85.5%)

47 (75%)

54 (98%)

0.02

Respiratory distress syndrome*

97 (82.2%)

42 (66.7%)

55 (100%)

0.04

Oxygen therapy*

115 (97.4%)

60 (95.2%)

55 (100%)

0.47

Past medical history*

    

 History of stroke

24 (20.3%)

6 (9.5%)

18 (32.7%)

0.08

 History of seizures

6 (5%)

6 (9.5%)

0

0.48

 Another neurologic diseases

57 (48.3%)

35 (55.5%)

22 (40%)

0.42

 No previous neurological disorders

31 (26.2%)

8 (12.6%)

23 (41.8%)

0.47

Death*

15 (12.7%)

4 (6.3%)

11 (20%)

0.37

Clinical manifestations*

    

 Disturbed conscious level

97 (82.2%)

45 (71.4%)

52 (94.5%)

0.14

 Confusion

37 (31.3%)

24 (38%)

13 (23.6%)

0.17

 Agitation

19 (16.1%)

12 (19%)

7 (12.7%)

0.31

Seizures

17 (14.4%)

7 (11.1%)

10 (18.8%)

0.94

 Headache

14 (11.8%)

10 (15.8%)

4 (7.2%)

0.30

 Coma

13 (11%)

9 (14.2%)

4 (7.2%)

0.62

  1. *Data are numbers of patients, and data in parentheses are percentages
  2. *Data are means, with ranges in parentheses and medians in brackets
  3. *P value less than 0.05 indicates a significant difference